Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 6/2021

01-06-2021 | Magnetic Resonance Imaging | Hepatobiliary-Pancreas

Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival

Authors: Jun Zhang, Zhenru Wu, Jian Zhao, Siyun Liu, Xin Zhang, Fang Yuan, Yujun Shi, Bin Song

Published in: European Radiology | Issue 6/2021

Login to get access

Abstract

Objective

Clinical evidence suggests that the response to immune checkpoint blockade depends on the immune status in the tumor microenvironment. This study aims to predict the immunophenotyping (IP) and overall survival (OS) of intrahepatic cholangiocarcinoma (ICC) patients using preoperative magnetic resonance imaging (MRI) texture analysis.

Methods

A total of 78 ICC patients were included and divided into inflamed (n = 26) or non-inflamed (n = 52) immunophenotyping based on the density of CD8+ T cells. The enhanced T1-weighted MRI in the arterial phase was employed with texture analysis. The logistic regression analysis was applied to select the significant features related to IP. The OS-related feature was determined by Cox proportional-hazards model and Kaplan-Meier analysis. IP and OS predictive models were developed using the selected features, respectively.

Results

Three wavelets and one 3D feature have favorable ability to discriminate IP, a combination of which performed best with an AUC of 0.919. The inflamed immunophenotyping had a better prognosis than the non-inflamed one. The 5-year survival rates of the two groups were 48.5% and 25.3%, respectively (p < 0.05). The only wavelet-HLH_firstorder_Median feature was associated with OS and used to build the OS predictive model with a C-index of 0.70 (95% CI, 0.57, 0.82), which could well stratify ICC patients into high- and low-risk groups. The 1-, 3-, and 5-year survival probabilities of the stratified groups were 62.5%, 30.0%, and 24.2%, and 89.5%, 62.2%, and 42.1%, respectively (p < 0.05).

Conclusion

The MRI texture signature could serve as a potential predictive biomarker for the IP and OS of ICC patients.

Key Points

• The MRI texture signature, including three wavelets and one 3D feature, showed significant associations with immunophenotyping of ICC, and all have favorable ability to discriminate immunophenotyping; a combination of the above features performed best with an AUC of 0.919.
• The only wavelet-HLH_firstorder_Median feature was associated with the OS of ICC and used to build the OS predictive model, which could well stratify ICC patients into high- and low-risk groups.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef
2.
3.
Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRef
4.
Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRef
5.
de Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29:3140–3145CrossRef
6.
Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13:143–158CrossRef
7.
Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121CrossRef
8.
Migden MR, Rischin D, Schmults CD et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351CrossRef
9.
Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520CrossRef
10.
Kansy BA, Concha-Benavente F, Srivastava RM et al (2017) PD-1 Status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res 77:6353–6364CrossRef
11.
Chowell D, Morris LGT, Grigg CM et al (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359:582–587CrossRef
12.
Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319CrossRef
13.
Sabbatino F, Villani V, Yearley JH et al (2016) PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res 22:470–478CrossRef
14.
Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330CrossRef
15.
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRef
16.
Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567CrossRef
17.
Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144CrossRef
18.
Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27:1492–1504CrossRef
19.
Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44CrossRef
20.
Sharma P, Allison JP (2015) The future ofimmune checkpoint therapy. Science 348(6230):56–61CrossRef
21.
Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028CrossRef
22.
Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571CrossRef
23.
Shields AF, Jacobs PM, Sznol M et al (2018) Immune modulation therapy and imaging: workshop report. J Nucl Med 59:410–417CrossRef
24.
Ku YJ, Kim HH, Cha JH et al (2016) Correlation between MRI and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. AJR Am J Roentgenol 207:1146–1151CrossRef
25.
Ku YJ, Kim HH, Cha JH et al (2018) Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 47:760–766CrossRef
26.
Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762CrossRef
27.
Sun R, Limkin EJ, Vakalopoulou M et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19:1180–1191CrossRef
28.
Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22:1865–1874CrossRef
29.
Zhang J, Huang Z, Cao L et al (2020) Differentiation combined hepatocellular and cholangiocarcinoma from intrahepatic cholangiocarcinoma based on radiomics machine learning. Ann Transl Med 8:119CrossRef
30.
Xu L, Yang P, Liang W et al (2019) A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. Theranostics 9:5374–5385CrossRef
31.
Liang W, Yang P, Huang R et al (2019) A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res 25:584–594CrossRef
32.
Wu W, Parmar C, Grossmann P et al (2016) Exploratory study to identify radiomics classifiers for lung cancer histology. Front Oncol 6:71PubMedPubMedCentral
33.
Ahmed AA, Elmohr MM, Fuentes D et al (2020) Radiomic mapping model for prediction of Ki-67 expression in adrenocortical carcinoma. Clin Radiol 75:479 e417–479 e422CrossRef
34.
Tixier F, Le Rest CC, Hatt M et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378CrossRef
35.
36.
Gu FM, Gao Q, Shi GM et al (2012) Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol 19:2506–2514CrossRef
37.
Liang W, Xu L, Yang P et al (2018) Novel nomogram for preoperative prediction of early recurrence in intrahepatic cholangiocarcinoma. Front Oncol 8:360CrossRef
38.
Ji GW, Zhu FP, Zhang YD et al (2019) A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol 29:3725–3735CrossRef
39.
Metadata
Title
Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival
Authors
Jun Zhang
Zhenru Wu
Jian Zhao
Siyun Liu
Xin Zhang
Fang Yuan
Yujun Shi
Bin Song
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 6/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07524-y

Other articles of this Issue 6/2021

European Radiology 6/2021 Go to the issue

Musculoskeletal

Conventional MRI-based subchondral trabecular biomarkers as predictors of knee osteoarthritis progression: data from the Osteoarthritis Initiative

Neuro

Comparison of automated and manual DWI-ASPECTS in acute ischemic stroke: total and region-specific assessment

Correction

Correction to: Fully automated body composition analysis in routine CT imaging using 3D semantic segmentation convolutional neural networks

Imaging Informatics and Artificial Intelligence

Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI

Correction

Correction to: Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma

Cardiac

Impact of chest wall deformity on cardiac function by CMR and feature-tracking strain analysis in paediatric patients with Marfan syndrome